BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2022 9:00:24 AM | Browse: 338 | Download: 651
 |
Received |
|
2022-01-23 03:46 |
|
Peer-Review Started |
|
2022-01-23 03:48 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-23 01:29 |
|
Revised |
|
2022-04-01 08:42 |
|
Second Decision |
|
2022-05-09 03:15 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-14 07:29 |
|
Articles in Press |
|
2022-05-14 07:29 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-01 00:43 |
|
Typeset the Manuscript |
|
2022-06-15 02:34 |
|
Publish the Manuscript Online |
|
2022-06-24 09:00 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Critical Care Medicine |
| Manuscript Type |
Minireviews |
| Article Title |
Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chou-Chin Lan, Po-Chun Hsieh, Chun-Yao Huang, Mei-Chen Yang, Wen-Lin Su, Chih-Wei Wu and Yao-Kuang Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yao-Kuang Wu, PhD, N/A, N/A, Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei 220, Taiwan. drbfci@yahoo.com.tw |
| Key Words |
Hemodialysis; Non-small-cell lung cancer; Epidermal growth factor receptor; Tyrosine-kinase inhibitors |
| Core Tip |
Lung cancer causes significant mortality worldwide. Patients with chronic renal failure increase the difficulty of treatment. Oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are effective treatment agents for non-small-cell lung cancer (NSCLC) patients. According to this review, EGFR-TKIs are suitable for treating NSCLC patients undergoing hemodialysis (HD) owing to their good response rates and tolerance. The main routes of elimination of EGFR-TKIs are via the liver and excretion via feces. The recommended doses and pharmacokinetics of EGFR-TKIs for patients undergoing HD are similar to those with normal renal function. The plasma protein binding of EGFR-TKIs is high, and it is not necessary to adjust the dose after HD. |
| Publish Date |
2022-06-24 09:00 |
| Citation |
Lan CC, Hsieh PC, Huang CY, Yang MC, Su WL, Wu CW, Wu YK. Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis. World J Clin Cases 2022; 10(19): 6360-6369 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i19/6360.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i19.6360 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
